

# ISO/TS 17137:2019 (E)

## Cardiovascular implants and extracorporeal systems — Cardiovascular absorbable implants

---

### Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms and definitions
4	Device design, fabrication, packaging, and use considerations
4.1	Classification
4.2	Intended clinical performance
4.3	Intended clinical use
4.4	Materials
4.5	Packaging, labelling, and sterilization
4.5.1	Packaging
4.5.1.1	General
4.5.1.2	Considerations for absorbable product
4.5.2	Labelling
4.5.2.1	Label(s)
4.5.2.2	Instructions for use (IFU)
4.5.3	Sterilization
4.5.3.1	General
4.5.3.2	Radiation sterilization
4.5.3.3	Ethylene oxide sterilization
4.5.3.4	Steam sterilization
4.5.3.5	Alternative sterilization
4.6	Product shelf-life considerations
4.6.1	General information
4.6.2	Real-time aging
4.6.3	Accelerated aging
4.7	Risk management
4.7.1	General
4.7.2	Failure modes
4.7.3	Risk mitigation
4.7.4	Specific aspects for absorbable implants
5	Design evaluation
5.1	Evaluation overview and general considerations
5.1.1	Overview
5.1.2	General considerations
5.1.3	Summary of in vitro evaluation steps
5.2	in vitro procedural evaluation
5.2.1	Conditioning of test samples
5.2.2	Assessment of delivery and placement
5.2.3	Assessment of initial function post-deployment
5.3	in vitro degradation evaluation
5.3.1	General
5.3.2	Sample conditioning
5.3.3	Mechanical evaluation
5.3.4	Cyclic fatigue durability evaluation
5.3.5	Physical/chemical degradation evaluation

- 5.3.5.1 Material and degradation product evaluation
- 5.3.6 Imaging compatibility evaluation
- 5.3.6.1 Evaluate using relevant imaging modalities
- 5.3.6.2 Radiopacity
- 5.3.6.3 MRI compatibility
- 5.4 Biological evaluation
- 5.4.1 General considerations
- 5.4.2 Sterilization considerations
- 5.4.3 Drug-device combination product considerations
- 5.5 in vitro-in vivo correlation
- 5.6 in vivo pre-clinical evaluation
- 5.6.1 Purpose
- 5.6.2 Specific objectives
- 5.6.3 Protocol
- 5.6.4 Data collection
- 5.6.5 Test report and additional information
- 5.7 Clinical evaluation
- 5.7.1 Purpose
- 5.7.2 Specific objectives
- 5.7.3 Clinical investigation plan
- 5.7.4 Data collection
- 5.7.5 Final report
- 5.7.6 Post market surveillance

**Annex A (informative) Explanation on nomenclature of absorb, degrade and related terms**

**Page count: 29**